We found that TRIM21 expression levels are potentially elevated in a wide spectrum of tumors (Supplementary Figure S1), including glioma, melanoma, pancreatic adenocarcinoma, testicular germ cell tumors, acute myeloid leukemia, cholangio carcinoma and colorectum adenocarcinoma. This evidence concerns the gene TRIM21 and central nervous system cancer.